Leave Your Message

Submit An Free Inquiry

Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.

AI Helps Write
AI Helps Write

Usoro ọgwụgwọ CAR-T maka Multiple Myeloma (MM)

    Nchịkọta

    Multiple Myeloma (MM) bụ ụdị ọrịa kansa nke na-emetụta mkpụrụ ndụ plasma na ụmị ọkpụkpụ. A maara ya maka ọdịdị dị mgbagwoju anya na nke na-agbanwe agbanwe, na-ebutekarị nlọghachi azụ na iguzogide ọgwụgwọ ọdịnala. Ọ bụ ezie na chemotherapy, transplants cell cell, na ọgwụ ọhụrụ emewo ka arụpụta ihe dị mma, ọtụtụ ndị ọrịa na-emesị nwee nguzogide ọgwụgwọ. CAR-T (Chimeric Antigen Receptor T-cell) ọgwụgwọ bụ ọgwụgwọ na-agbawa obi nke gosipụtara ihe ịga nke ọma dị ịrịba ama n'ịgwọ ọtụtụ myeloma na-emegharịghachi na refractory, na-enye ihe ngwọta dị mma maka ndị ọrịa nwere oke nhọrọ.

    Kedu ihe bụ ọgwụgwọ CAR-T maka MM?

    Usoro ọgwụgwọ CAR-T gụnyere imegharị mkpụrụ ndụ T nke onye ọrịa ka ọ mata ma wakpo mkpụrụ ndụ kansa nke ọma. Maka otutu myeloma, a na-emezi mkpụrụ ndụ CAR-T iji gbado anya BCMA (B-cell maturation antigen), protein dị n'elu sel myeloma. Mgbe emezichara ya site na mkpụrụ ndụ ihe nketa, a na-agbanyeghachi mkpụrụ ndụ T ndị a n'ime ahụ onye ọrịa, ebe ha na-achọ ma bibie mkpụrụ ndụ kansa, nke nwere ike ibute mgbaghara na ịdị ogologo oge.

    Uru dị mkpa nke ọgwụgwọ CAR-T maka ọtụtụ Myeloma

    • Ịrụ ọrụ dị elu na Nlaghachi azụ/Ntugharị MM: Usoro ọgwụgwọ CAR-T egosila nnukwu ihe ịga nke ọma na ndị ọrịa nwere nlọghachi azụ ma ọ bụ refractory multiple myeloma, na-enwetakarị mgbaghara zuru oke ma ọ bụ obere ọrịa fọdụrụnụ (MRD).
    • Ezubere iche nkenkeSite n'ichebe BCMA, ọgwụgwọ CAR-T na-awakpo mkpụrụ ndụ myeloma kpọmkwem, na-echekwa anụ ahụ dị mma ma na-ebelata mmetụta ndị ọzọ ma e jiri ya tụnyere ọgwụgwọ nkịtị.
    • Ahaziri ahaziri na nke ọhụrụUsoro ọgwụgwọ ahụ na-eji mkpụrụ ndụ T nke onye ọrịa, na-ahụ na atụmatụ ọgwụgwọ ahaziri nke ọma. Nke a na-enyekwa aka belata ihe ize ndụ nke ịjụ.
    • Mgbaghara ogologo oge: Ọtụtụ ndị ọrịa na-agwọ ọrịa CAR-T na-enweta nzaghachi na-adịgide adịgide, yana ụfọdụ na-edobe mgbaghara ruo ọtụtụ afọ, ọbụlagodi mgbe ọgwụgwọ ndị ọzọ dara.

    Usoro ọgwụgwọ

    • Nchịkọta nke cell T: Nzọụkwụ mbụ gụnyere ịnakọta T-cell n'ọbara onye ọrịa site na iji leukapheresis, usoro yiri inye onyinye ọbara.
    • Injinia T-cell: A na-eziga cell T-cell ndị a na ụlọ nyocha, ebe a na-emezigharị ha site na mkpụrụ ndụ ihe nketa iji gosipụta CAR kpọmkwem maka BCMA, na-eme ka ha nwee ike ịchọpụta na igbu mkpụrụ ndụ myeloma.
    • Infusion nke mkpụrụ ndụ CAR-T: Mgbe mgbasawanye na ụlọ nyocha ahụ, a na-agbanyeghachi mkpụrụ ndụ T-engineer azụ n'ọbara onye ọrịa site na IV.
    • Nleba anya na mgbake: Mgbe infusion gasịrị, a na-enyocha ndị ọrịa maka mmetụta ndị nwere ike ime dị ka cytokine release syndrome (CRS) ma ọ bụ neurotoxicity. Mmetụta ndị a na-ejikarị eme ihe site na enyemaka ahụike na nlekota.

    Kedu ihe kpatara ịhọrọ ọgwụgwọ BIOOCUS CAR-T maka ọtụtụ Myeloma?

    • Teknụzụ ọgbara ọhụrụ CAR-TBIOOCUS na-eji ọganihu kachasị ọhụrụ na teknụzụ CAR-T iji hụ na ọgwụgwọ kachasị mma na nsonaazụ kacha mma maka ndị ọrịa MM.
    • Ọkachamara ahụike nke ụwa: Ndị ọkachamara anyị na hematology na immunotherapy na-enye nlekọta nkeonwe, na-ahụ na onye ọ bụla nwere ike ịnweta ọgwụgwọ kachasị mma maka ọnọdụ ha pụrụ iche.
    • Ndekọ egwu egosipụtara: Anyị ejirila ọgwụgwọ CAR-T gwọọ ọtụtụ ndị ọrịa MM, ma ọtụtụ enwetala mgbaghara dị ịrịba ama, na-adịte aka.
    • Nkwado zuru oke maka ndị ọrịa mba ụwaBIOOCUS na-enye nkwado zuru oke maka ndị ọrịa mba ụwa, na-eduzi gị site na usoro ọ bụla nke usoro ọgwụgwọ, site na ndụmọdụ mbụ na nlekọta nlekọta ọgwụgwọ.

    Ihe akaebe na-ahụ maka ụlọ ọgwụ na ọnụego ihe ịga nke ọma

    Data ụlọ ọgwụ

    Ngosipụta maka CD19+20CAR-T:Ndị ọrịa nwere lymphoma na-abụghị Hodgkin B-cell

    Ọnụego otu ọnwa CR

    Ọnụego PR otu ọnwa

    Otu ọnwa ma ọ bụ ọnụego

    CRS≥3

    CRES≥3

    71.95% (59/82)

    25.6 (21/82)

    97.55 (80/82)

    12.19% (10/82)

    0

    Ngosipụta maka CD19+22CAR-T:Ọgwụgwọ nke CD19 nlọghachite na refractory nnukwu B-lymphocytic leukemia ndị ọrịa.

    Ọnụego otu ọnwa CR

    Ọnụego PR otu ọnwa

    Otu ọnwa ma ọ bụ ọnụego

    CRS≥3

    CRES≥3

    92.1% (35/38)

    7.9% (3/38)

    100% (38/38)

    15.79% (6/38)

    0

    Ngosipụta maka BCMACAR-T:Ọgwụgwọ nke nlọghachi azụ na refractory multiple myeloma

    Ọnụego otu ọnwa CR

    Ọnụego PR otu ọnwa

    Otu ọnwa ma ọ bụ ọnụego

    CRS≥3

    CRES≥3

    72.41% (21/29)

    27.59% (8/29)

    100% (29/29)

    6.9% (2/29)

    0

    Submit An Free Inquiry

    Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.

    AI Helps Write